Johnson & Johnson announced today that scientists at Beth Israel Deaconess Medical Center (BIDMC), Crucell Holland B.V, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and several other collaborators today published results from a preclinical study of an HIV vaccine regimen used in in non-human primates. The study, published in the online edition of Science, suggests that a "heterologous prime-boost" vaccine regimen—which first primes the immune system, then boosts the immune system to increase the response, could ultimately prove to be a strategy for protecting against global human immunodeficiency virus (HIV-1) infection.
Google Reportedly Set to Launch Tool Revealing Battery Degradation Over Time for Phones and Tablets, Says Android Authority.
When talking about EVs, kWh and kW are often mentioned without context, but neither is as complicated as you might think.
Pair it with the company's glucose monitoring patch for even more data.
